Article

Correlation between Glycation-Related Biomarkers and Quality of Life in the General Japanese Population: The Iwaki Cross-Sectional Research Study

Masaya Tsubokawa 1,2,*, Miyuki Nishimura 2, Koichi Murashita 3, Takuro Iwane 3 and Yoshinori Tamada 1

1 Innovation Center for Health Promotion, Graduate School of Medicine, Hirosaki University, Hirosaki 036-8562, Japan; y.tamada@hirosaki-u.ac.jp
2 Health Science Research Center, FANCL Research Institute, Yokohama 244-0806, Japan; nishimura_miyuki@fancl.co.jp
3 Center of Innovation Research Initiatives Organization, Hirosaki University, Hirosaki 036-8562, Japan; murasita@hirosaki-u.ac.jp (K.M.); i-tak@hirosaki-u.ac.jp (T.I.)
* Correspondence: tsubokawa_masaya@fancl.co.jp; Tel.: +81-045-820-3659

Abstract: The correlation between diabetes-related biomarkers and quality of life (QOL) remains unclear. In this cross-sectional study, we investigated the correlation between diabetes-related biomarkers and QOL in a general Japanese population who underwent health checkups as a part of the Iwaki Health Promotion Project. Male and female participants aged ≥ 20 years from Iwaki District, Hirosaki City, Aomori Prefecture who participated in the 2019 medical evaluation were recruited. QOL was evaluated using the Short Form Health Survey 36 (SF-36). Fasting blood glucose, homeostatic model assessment-estimated insulin resistance (HOMA-IR), hemoglobin A1c (HbA1c), glycoalbumin, and plasma pentosidine were also evaluated as diabetes-related markers. Of the 1065 recruited participants, 1053 completed the clinical and QOL evaluations. Multivariate regression analysis revealed that upregulated diabetes-related markers levels were correlated with decreased SF-36 scores. Blood glucose, HOMA-IR, HbA1c, glycoalbumin, and plasma pentosidine were also evaluated as diabetes-related markers. Of the 1065 recruited participants, 1053 completed the clinical and QOL evaluations. Multivariate regression analysis revealed that upregulated diabetes-related markers levels were correlated with decreased SF-36 scores. Blood glucose, HOMA-IR, HbA1c, glycoalbumin, and plasma pentosidine levels were correlated with general health. Moreover, plasma pentosidine levels were correlated with role physical, social functioning, and role emotional in addition to general health. These results indicated that the levels of diabetes-related biomarkers, particularly the levels of plasma pentosidine, a glycation marker, were associated with QOL in our cohort.

Keywords: quality of life; diabetes; glycation; HbA1c; glycoalbumin; pentosidine

1 Introduction

Quality of life (QOL), a multidimensional concept, corresponds to the general well-being status of individuals [1] and is an important measure of overall health [2]. QOL represents the goal of all health interventions and is assessed in terms of physical and social function along with mental well-being [3]. Studies on QOL involve various patient groups and research designs [4]. Traditionally, the principal endpoints in medical and health research have been biomedical outcomes rather than QOL outcomes. However, research over the past few decades focused on the QOL of patients, which increased the application of QOL assessments [5]. Increased human life expectancy shifted the research focus to improving the QOL and maintaining good overall health [6]. Leading global studies on health care have emphasized the importance of QOL [7].

The incidence of diabetes mellitus has increased with the aging population, which, due to the required treatment, has created a major burden on health care systems [8]. As a result, patients with diabetes have low QOL [3]. The goal of early diagnosis and treatment of diabetes is to improve QOL [9] since the progression of diabetes affects the QOL [10]; therefore, diabetes prevention strategies are essential [11]. However, studies
on the general population, including healthy individuals, are limited to the correlation between hyperglycemia and depressive symptoms [12]. In addition, complications such as coronary artery disease, renal failure, blindness, and microvascular and macrovascular disease are the major factors affecting the QOL of patients with diabetes [9]. The formation and accumulation of glycation end product (AGE) represent one of the main pathogenic mechanisms underlying diabetes-associated complications [13], although the relationship between AGE and QOL remains to be fully investigated.

Therefore, this study investigated the correlation between several diabetes-related biomarkers, including glycation markers associated with AGEs, and various QOL-related parameters in the general Japanese population who underwent health examinations as part of the Iwaki City Health Examination Project.

2. Participants and Methods

2.1. Participants and Analysis

Medical examination under the Iwaki Health Promotion Project has taken place annually since 2005 to prevent lifestyle-related diseases, maintain and promote public health of the residents in the Iwaki District of Hirosaki City [14]. Male and female participants aged ≥ 20 years residing in Iwaki District, Hirosaki City, Aomori Prefecture who participated in the 2019 medical examination were recruited. This cross-sectional study recruited 1065 participants, of which 1053 participants completed the clinical examination and QOL evaluation and were therefore enrolled. The study protocol was approved by the Ethics Review Board of the Hirosaki University School of Medicine (approval numbers: 2019-009) and conducted according to the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants [15].

2.2. Clinical Features

All laboratory tests were performed under fasting conditions in the morning [15]; body mass index (BMI; calculated using BMI = weight (kg)/height (m)^2) was assessed during physical examination. The systolic and diastolic blood pressure were recorded using an automated sphygmomanometer Elemano2 (Terumo Co., Ltd., Tokyo, Japan) while the participants were in a seated position. The following hematological parameters were analyzed: the glucose metabolic capacity-related parameters of blood glucose levels and homeostasis model assessment-estimated insulin resistance (HOMA-IR) values; the glycation-related parameters hemoglobin A1c (HbA1c), glycoalbumin, and plasma pentosidine levels; the lipid metabolic capacity-related parameters triglyceride, total cholesterol, high-density lipoprotein, and low-density lipoprotein levels; the liver function-related parameters alanine transaminase, aspartate transaminase, and γ-glutamyl transferase; the renal function-related parameters creatinine and urea nitrogen levels. Blood samples were collected from the peripheral veins with the participants in the supine position and tested by LSI Medience Co., Ltd. (Tokyo, Japan) [15]. To evaluate lifestyle-related parameters, the results of the survey regarding diabetes mellitus, dyslipidemia, presence of hypertension, smoking habit, alcohol consumption, and exercise (non-winter and winter seasons) were also analyzed.

2.3. Diabetes-Related Biomarkers

Blood glucose, HbA1c, and glycoalbumin levels were determined using enzymatic methods with JCA-BM9130 and JCA-BM8060 (Japan Electron Optics Laboratory Co., Ltd., Tokyo, Japan). Plasma pentosidine levels were determined using high-performance liquid chromatography with Acquity UPLC H-CLASS (Nihon Waters Co., Ltd., Tokyo, Japan), while insulin levels were determined using chemiluminescent immunoassay methods with Architect i2000 SR (Abbott Japan LLC., Tokyo, Japan). HOMA-IR was calculated as follows: HOMA-IR = (blood glucose levels × blood insulin levels)/405 [16,17].
2.4. QOL Evaluation

The Short Form Health Survey 36 (SF-36) is structured based on a universal concept of health and is not limited to a specific disease, and hence can be used to measure the QOL of patients with various diseases along with healthy subjects. QOL can be comparatively analyzed among patients with different diseases. Additionally, the health of patients can be compared with that of the general population.

SF-36 comprises multiple questions to measure the following eight health parameters: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health [18,19].

The SF-36 score for each parameter is interpreted as follows:

- **Physical functioning**
  - Low score: Difficulty with performing routine activities, such as bathing or dressing.
  - High score: Can perform all types of activities, including strenuous activities.

- **Role physical**
  - Low score: Difficulties with working or performing regular activities in the last month due to physical limitations.
  - High score: No difficulties with working or performing routine activities in the last month due to physical limitations.

- **Bodily pain**
  - Low score: Routine work markedly hampered by severe pain in the last month.
  - High score: No physical pain in the last month that would interfere with routine work.

- **General health**
  - Low score: Poor health that gradually worsened.
  - High score: Good health.

- **Vitality**
  - Low score: Tiredness and exhaustion at any time during the last month.
  - High score: Feeling energetic at all times during the last month.

- **Social functioning**
  - Low score: Difficulty socializing with family, friends, neighbors, or peers in the last month for physical or psychological reasons.
  - High score: Physical or psychological reasons did not affect the ability to socialize with family, friends, neighbors, or peers in the last month.

- **Role emotional**
  - Low score: Difficulty with working or performing routine activities in the last month due to psychological reasons.
  - High score: Psychological reasons did not interfere with working or performing routine activities in the last month.

- **Mental health**
  - Low score: Nervous and depressed mood at all times during the last month.
  - High score: Calm, happy, and relaxed feeling during the last month.

2.5. Statistical Analysis

Continuous variables among the clinical characteristics of the participants are represented as the mean ± standard deviation, whereas the categorical variables are represented as the sample size and percentage (%). To investigate diabetes biomarkers associated with QOL, univariate regression analysis was performed using the SF-36 scores as the dependent variable and each diabetes-related biomarker as the independent variables. In the multivariate analysis, model 1 (adjusted for age, sex, and BMI) and model 2 (adjusted for antihypertensive medications, exercise, smoking, and alcohol consumption in addition to age, sex, and BMI) were performed. In addition, we performed multivariate regression analysis using SF-36 scores as the dependent variable and age, sex, and BMI as the independent variables. The regression coefficient (β) was calculated using the standard least squares method. In these analyses, the significance level was set at \( p < 0.05 \) in two-tailed tests, and
95% confidence interval (CI) for the regression coefficient ($\beta$) was calculated. We used JMP® Ver.16 software (SAS Institute, Inc., Cary, NC, USA) in these statistical analyses [15].

3. Results

Table 1 lists the clinical characteristics of our study cohort. The characteristics of the study cohort were as follows: sex distribution with 59.2% females and 40.8% males; mean age, 52.6 years; mean BMI, 23.0 kg/m$^2$. For the SF-36 scores, the vitality and general health were relatively low. The rates of lifestyle-related diseases were highest in high blood pressure followed by hyperlipidemia and diabetes.

Table 1. Clinical characteristics of the study cohort.

| Continuous Variables | Total (n = 1053) | Males (n = 430) | Females (n = 623) |
|----------------------|-----------------|----------------|------------------|
|                      | Mean (SD)       | Mean (SD)      | Mean (SD)        |
| Age (years)          | 52.6 (15.24)    | 52.4 (15.03)   | 52.7 (15.40)     |
| BMI (kg/m$^2$)       | 23.0 (3.62)     | 24.1 (3.47)    | 22.3 (3.56)      |
| HbA1c (%)            | 5.7 (0.62)      | 5.7 (0.69)     | 5.7 (0.56)       |
| Glycoalbumin (%)     | 14.6 (1.96)     | 14.4 (2.33)    | 14.7 (1.64)      |
| Blood glucose (mg/dL)| 96.0 (16.26)    | 99.3 (17.54)   | 93.7 (14.91)     |
| Blood insulin (µU/mL)| 5.1 (2.79)      | 5.1 (3.09)     | 5.1 (2.56)       |
| HOMA IR (-)          | 1.2 (0.83)      | 1.3 (0.92)     | 1.2 (0.76)       |
| Triglyceride (mg/dL) | 97.7 (85.08)    | 124.6 (116.91) | 79.1 (44.39)     |
| Total cholesterol (mg/dL) | 204.5 (34.39) | 201.9 (34.31) | 206.3 (34.35)   |
| HDL cholesterol (mg/dL) | 65.1 (16.59)   | 58.4 (14.76)   | 69.7 (16.22)     |
| LDL cholesterol (mg/dL) | 116.0 (29.66)  | 116.2 (29.17)  | 115.9 (30.02)   |
| ALT (U/L)            | 20.8 (13.91)    | 26.4 (16.96)   | 16.9 (9.58)      |
| AST (U/L)            | 21.8 (7.88)     | 23.8 (8.42)    | 20.5 (7.17)      |
| γ-GTP (U/L)          | 32.5 (39.62)    | 48.0 (55.19)   | 21.8 (16.47)     |
| Creatinine (mg/dL)   | 0.7 (0.52)      | 0.9 (0.70)     | 0.6 (0.31)       |
| Urea nitrogen (mg/dL)| 14.5 (4.54)     | 15.4 (4.51)    | 13.9 (4.46)      |
| Plasma pentosidine (pmol/mL) | 26.6 (16.09) | 26.2 (18.66) | 26.9 (14.04)   |
| SBP (mmHg)           | 120.8 (16.96)   | 123.9 (16.86)  | 118.7 (16.71)   |
| DBP (mmHg)           | 76.9 (11.36)    | 79.6 (11.54)   | 75.0 (10.83)     |
| Physical functioning (points) | 90.3 (15.31) | 92.1 (14.02) | 89.1 (16.04)   |
| Role physical (points) | 90.6 (17.75)  | 92.7 (16.43)   | 89.2 (18.48)     |
| Bodily pain (points) | 73.3 (22.76)    | 76.0 (22.57)   | 71.4 (22.71)     |
| General health (points) | 61.3 (17.55)  | 62.3 (17.07)   | 60.6 (17.85)     |
| Vitality (points)    | 62.3 (19.08)    | 65.0 (19.15)   | 60.3 (18.81)     |
| Social functioning (points) | 91.6 (16.08) | 93.0 (15.12) | 90.6 (16.65)   |
| Role emotional (points) | 91.8 (17.32)  | 92.6 (17.27)   | 91.4 (17.34)     |
| Mental health (points) | 75.3 (17.02)  | 76.8 (16.88)   | 74.3 (17.05)     |

| Categorical variables | Total (%) | Males (%) | Females (%) |
|-----------------------|-----------|-----------|-------------|
| Diabetes mellitus     | 988 (93.9%) | 399 (92.8%) | 589 (94.7%) |
| Yes                   | 64 (6.1%)  | 31 (7.2%)  | 33 (5.3%)   |
| Hyperlipidemia        | 872 (83.0%) | 354 (82.7%) | 518 (83.3%) |
| Yes                   | 178 (17.0%) | 74 (17.3%)  | 104 (16.7%) |
| High blood pressure   | 788 (74.8%) | 301 (70.0%) | 487 (78.2%) |
| Yes                   | 265 (25.2%) | 129 (30.0%) | 136 (21.8%) |
| Antihypertensive medication use | 807 (76.6%) | 313 (72.8%) | 494 (79.3%) |
| Yes                   | 246 (23.4%) | 117 (27.2%) | 129 (20.7%) |
| Exercising (non-winter seasons) | 819 (77.9%) | 334 (77.9%) | 485 (77.8%) |
| Yes                   | 233 (22.1%) | 95 (22.1%)  | 138 (22.2%) |
Table 1. Cont.

| Categorical variables                  | Total (n = 1053) | Males (n = 430) | Females (n = 623) |
|----------------------------------------|-----------------|----------------|------------------|
| **Exercising (winter season)**          |                 |                |                  |
| No                                     | 817 (78.1%)     | 336 (78.7%)    | 481 (77.7%)      |
| Yes                                    | 229 (21.9%)     | 91 (21.3%)     | 138 (22.3%)      |
| **Smoking**                            |                 |                |                  |
| No                                     | 669 (64.0%)     | 181 (42.5%)    | 488 (78.7%)      |
| Yes                                    | 180 (17.2%)     | 125 (29.3%)    | 55 (8.9%)        |
| **Alcohol consumption**                |                 |                |                  |
| No                                     | 501 (48.1%)     | 121 (28.3%)    | 380 (61.8%)      |
| Yes                                    | 501 (48.1%)     | 121 (28.3%)    | 380 (61.8%)      |

BMI, body mass index; HbA1c, hemoglobin A1c; HOMA-IR, homeostatic model assessment-estimated insulin resistance; HDL, high-density cholesterol; LDL, low-density cholesterol; ALT, alanine transaminase; AST, aspartate transaminase; γ-GTP, γ-glutamyl transferase; SBP, systolic blood pressure; DBP, diastolic blood pressure; SD, standard deviation.

Tables 2–6 show the results of univariate and multivariate regression analyses of the association between SF-36 scores and diabetes-related biomarkers.

Table 2. Correlation between SF-36 scores and blood glucose levels (mg/dL).

| Characteristics | Univariate | Model 1 | Model 2 |
|-----------------|------------|---------|---------|
|                 | β          | 95% CI  | p-Value | β          | 95% CI  | p-Value | β          | 95% CI  | p-Value |
| Physical functioning | −0.153     | −0.209 to −0.097 | < 0.001 | 0.012     | −0.044 to 0.068 | 0.671  | 0.019     | −0.037 to 0.075 | 0.499 |
| Role physical   | −0.101     | −0.167 to −0.035 | 0.003  | 0.002     | −0.068 to 0.072 | 0.958  | 0.015     | −0.057 to 0.087 | 0.685 |
| Bodily pain     | −0.117     | −0.201 to −0.032 | 0.007  | −0.107    | −0.078 to 0.756 | 0.069  | 0.009     | −0.084 to 0.103 | 0.847 |
| General health  | −0.140     | −0.205 to −0.075 | < 0.001 | −0.107    | −0.034 to 0.004 | 0.081  | 0.014     | −0.154 to 0.008 | 0.303 |
| Vitality        | 0.063      | 0.086  to 0.134 | 0.801  | −0.018    | −0.096 to 0.061 | 0.661  | 0.014     | −0.093 to 0.066 | 0.736 |
| Social functioning | 0.001   | 0.059 to 0.061 | 0.982  | 0.001     | −0.066 to 0.068 | 0.972  | 0.005     | −0.064 to 0.074 | 0.891 |
| Role emotional  | −0.005     | −0.070 to −0.059 | 0.875  | 0.031     | −0.041 to 0.104 | 0.397  | 0.002     | −0.045 to 0.103 | 0.438 |
| Mental health   | 0.050      | 0.023 to 0.094 | 0.345  | 0.019     | −0.090 to 0.052 | 0.603  | 0.022     | −0.094 to 0.050 | 0.544 |

Model 1: adjusted for age, sex, and BMI. Model 2: adjusted for age, sex, BMI, antihypertensive medication, exercise (non-winter and winter seasons), smoking, and alcohol consumption. BMI, body mass index; CI, confidence interval; SF-36, Short Form Health Survey 36.

Table 3. Correlation between SF-36 scores and HOMA-IR values.

| Characteristics | Univariate | Model 1 | Model 2 |
|-----------------|------------|---------|---------|
|                 | β          | 95% CI  | p-Value | β          | 95% CI  | p-Value | β          | 95% CI  | p-Value |
| Physical functioning | −1.795     | −2.907  to −0.684 | 0.002  | 0.373     | −0.786 to 1.532 | 0.528  | 0.719     | −0.455 to 1.893 | 0.220 |
| Role physical   | −0.913     | −2.216  to 0.380 | 0.166  | −0.040    | −1.499 to 1.419 | 0.957  | 0.330     | −1.184 to 1.844 | 0.669 |
| Bodily pain     | −1.431     | −3.088  to 0.226 | 0.091  | 0.561     | −1.359 to 2.481 | 0.566  | 0.769     | −1.197 to 2.734 | 0.443 |
| General health  | −3.503     | −4.765  to −2.241 | < 0.001 | 3.328     | −4.624 to −1.832 | < 0.001 | 0.418     | −1.357 to −1.111 | 0.001 |
| Vitality        | −0.135     | −1.526  to 1.256 | 0.849  | −0.269    | −1.893 to 1.355 | 0.745  | 0.116     | −1.558 to 1.791 | 0.892 |
| Social functioning | −0.961     | −2.132  to 0.210 | 0.107  | −0.470    | −1.861 to 0.920 | 0.507  | −0.548     | −1.991 to 0.895 | 0.456 |
| Role emotional  | −1.134     | −2.395  to 0.126 | 0.078  | −0.968    | −2.466 to 0.531 | 0.206  | −0.783     | −2.333 to 0.768 | 0.322 |
| Mental health   | −0.196     | −1.437  to 1.045 | 0.756  | −0.468    | −1.936 to 1.000 | 0.532  | −0.387     | −1.901 to 1.126 | 0.616 |

Model 1: adjusted for age, sex, and BMI. Model 2: adjusted for age, sex, BMI, antihypertensive medication, exercise (non-winter and winter seasons), smoking, and alcohol consumption. BMI, body mass index; CI, confidence interval; HOMA-IR, homeostatic model assessment-estimated insulin resistance; SF-36, Short Form Health Survey 36.
### Table 4. Correlation between SF-36 scores and HbA1c levels (%).

| Characteristics         | Model 1 | Model 2 |
|-------------------------|---------|---------|
|                         | β       | 95% CI  | p-Value | β       | 95% CI  | p-Value |
| Physical functioning    | –4.859  | –6.333  | <0.001  | –0.728  | –2.156  | <0.001  | –0.427  | –1.853  | <0.001  |
| Role physical           | –4.249  | –5.972  | <0.001  | –1.715  | –3.511  | <0.001  | –1.320  | –3.156  | <0.001  |
| Bodily pain             | –3.418  | –5.642  | 0.003   | –0.505  | –2.872  | 0.067   | –0.060  | –2.448  | 0.001   |
| General health          | –4.728  | –6.426  | <0.001  | –3.824  | –5.670  | <0.001  | –3.321  | –5.184  | <0.001  |
| Vitality                | –0.142  | –2.014  | 1.730   | 0.882   | –1.894  | 1.005   | 0.063   | –1.636  | 0.001   |
| Social functioning      | –1.325  | –2.901  | 0.250   | 0.994   | –1.249  | –3.012  | 0.044   | 0.137   | 0.083   |
| Role emotional          | –1.206  | –2.904  | 0.492   | 0.164   | –0.438  | 2.287   | 1.412   | 0.643   | 0.334   |
| Mental health           | –0.008  | –1.678  | 1.662   | 0.992   | –1.055  | 2.864   | 0.754   | 0.253   | 1.130   |

Model 1: adjusted for age, sex, and BMI. Model 2: adjusted for age, sex, BMI, antihypertensive medication, exercise (non-winter and winter seasons), smoking, and alcohol consumption. BMI, body mass index; CI, confidence interval; SF-36, Short Form Health Survey 36.

### Table 5. Correlation between SF-36 scores and glycoalbumin levels (%).

| Characteristics         | Model 1 | Model 2 |
|-------------------------|---------|---------|
|                         | β       | 95% CI  | p-Value | β       | 95% CI  | p-Value |
| Physical functioning    | –1.482  | –1.948  | <0.001  | –0.374  | –0.813  | <0.001  | –0.290  | –0.725  | <0.001  |
| Role physical           | –1.543  | –2.084  | <0.001  | –0.659  | –1.210  | <0.001  | –0.536  | –1.096  | <0.001  |
| Bodily pain             | –1.062  | –1.763  | 0.003   | –0.341  | –1.069  | 0.038   | 0.359   | –0.212  | –0.941  | 0.517   |
| General health          | –1.226  | –1.794  | <0.001  | –1.057  | –1.626  | <0.001  | –0.983  | –1.453  | <0.001  |
| Vitality                | 0.041   | –0.550  | 0.631   | 0.893   | –0.447  | 1.063   | 0.168   | 0.154   | –0.351  |
| Social functioning      | –0.222  | –0.719  | 0.276   | 0.382   | –0.295  | 0.822   | 0.232   | 0.327   | 0.232   |
| Role emotional          | –0.474  | –1.089  | 0.061   | 0.083   | –0.276  | –0.845  | 0.292   | 0.341   | –0.227  |
| Mental health           | –0.057  | –0.584  | 0.470   | 0.831   | –0.339  | 0.895   | 0.218   | 0.233   | –0.323  |

Model 1: adjusted for age, sex, and BMI. Model 2: adjusted for age, sex, BMI, antihypertensive medication, exercise (non-winter and winter seasons), smoking, and alcohol consumption. BMI, body mass index; CI, confidence interval; SF-36, Short Form Health Survey 36.

### Table 6. Correlation between SF-36 scores and pentosidine levels (pmol/mL).

| Characteristics         | Model 1 | Model 2 |
|-------------------------|---------|---------|
|                         | β       | 95% CI  | p-Value | β       | 95% CI  | p-Value |
| Physical functioning    | –0.143  | –0.200  | <0.001  | –0.040  | –0.093  | <0.001  | –0.012  | 0.132   | <0.001  |
| Role physical           | –0.191  | –0.256  | <0.001  | –0.109  | –0.175  | <0.001  | –0.044  | 0.001   | –0.312  |
| Bodily pain             | –0.102  | –0.187  | <0.016  | 0.019   | –0.042  | –0.129  | 0.045   | 0.341   | –0.037  |
| General health          | –0.108  | –0.173  | <0.002  | –0.094  | –0.162  | <0.002  | –0.025  | 0.007   | –0.093  |
| Vitality                | 0.037   | –0.028  | 0.109   | 0.311   | –0.019  | 0.093   | 0.054   | 0.608   | –0.002  |
| Social functioning      | –0.057  | –0.117  | 0.004   | 0.065   | –0.075  | –0.138  | –0.012  | 0.019   | –0.073  |
| Role emotional          | –0.114  | –0.179  | –0.049  | 0.001   | –0.103  | –0.171  | –0.035  | 0.003   | –0.073  |
| Mental health           | 0.016   | –0.048  | 0.080   | 0.629   | –0.015  | 0.082   | 0.051   | 0.656   | –0.007  |

Model 1: adjusted for age, sex, and BMI. Model 2: adjusted for age, sex, BMI, antihypertensive medication, exercise (non-winter and winter seasons), smoking, and alcohol consumption. BMI, body mass index; CI, confidence interval; SF-36, Short Form Health Survey 36.

A multivariate regression analysis (Model 2) adjusted for age, sex, BMI, antihypertensive medication, exercise (non-winter and winter seasons), smoking, and alcohol consumption revealed that general health was negatively correlated with upregulated blood glucose levels ($\beta = -0.811$; 95% CI = –0.154 to –0.008; $p = 0.030$), HOMA-IR values ($\beta = -2.646$; 95% CI = –4.181 to –1.111; $p = 0.001$), HbA1c levels ($\beta = -3.321$; 95% CI = –5.184 to –1.458; $p < 0.001$), glycoalbumin levels ($\beta = -0.883$; 95% CI = –1.453 to –0.313; $p = 0.002$), and plasma pentosidine levels ($\beta = -0.093$; 95% CI = –0.164 to –0.021; $p = 0.011$). Plasma pentosidine levels were negatively correlated with role physical ($\beta = -0.112$; 95% CI = –0.182 to –0.042; $p = 0.002$), social functioning ($\beta = -0.073$; 95% CI = –0.140 to –0.006; $p = 0.033$), and role emotional ($\beta = -0.073$; 95% CI = –0.144 to –0.001; $p = 0.048$) in addition to general health.
A multivariate regression analysis (Model 2) also showed that levels of diabetes biomarkers such as blood glucose, HOMA-IR, HbA1c, glycoalbumin, and plasma pentosidine were associated with the general health of the SF-36 scores. The p-value, which indicates significance, was the smallest for HbA1c, followed by HOMA-IR, glycoalbumin, plasma pentosidine, and blood glucose. Moreover, the level of the glycation marker plasma pentosidine was associated with lower SF-36 scores such as role physical, social functioning, and role emotional compared with other markers.

Table S1 shows the results of multivariate regression analysis when SF-36 scores were used as the dependent variable, while age, sex, and BMI were used as the independent variables. Age was negatively correlated with physical functioning, role physical, bodily pain, general health, and role emotional. Female was negatively correlated with physical functioning, role physical, bodily pain, general health, vitality, social functioning, and mental health. BMI was negatively correlated with physical functioning, bodily pain, general health, and social functioning.

4. Discussion

Among the general Japanese population who participated in the Iwaki Health Promotion Project medical examination, blood glucose, HOMA-IR, HbA1c, glycoalbumin, and plasma pentosidine levels were correlated with some SF-36 scores after adjusting for age, sex, BMI, antihypertensive medication, exercise (non-winter and winter seasons), smoking, and alcohol consumption. Therefore, the levels of diabetes-related biomarkers were associated with QOL in our cohort. Particularly, the level of plasma pentosidine, a glycation marker, was associated with QOL. The correlation between QOL and plasma pentosidine levels was not previously reported.

Diabetes markedly deteriorates the QOL of patients to varying degrees [20–23]. Previous studies compared the QOL of patients with type 2 diabetes with that of healthy subjects. In contrast, we examined the correlation between QOL and diabetes-related biomarkers and found that the levels of diabetes biomarkers such as blood glucose, HOMA-IR, HbA1c, glycoalbumin, and plasma pentosidine were associated with the general health of the SF-36 scores. In addition, poorer general health was associated with aging and obesity along with diabetes-related markers. General health is impaired by the deterioration of the glucose metabolic capacity, which is associated with aging and obesity. Hyperglycemia may contribute to decreasing QOL such as exacerbating symptoms of fatigue and depression [24,25] by modulating physiological pathways (including inflammatory processes) and downregulating neurotrophic functions [26–29]. Additionally, previous studies demonstrated that individuals with low-QOL-associated anxiety are at high risk for developing diabetes [30]. Therefore, to improve QOL, it is important to educate the general population regarding the high risk of low QOL among individuals in a prediabetic state.

Furthermore, plasma pentosidine levels were negatively correlated with SF-36 scores such as role physical, social functioning, and role emotional compared with other diabetes-related markers. Deterioration in role physical and role emotional were associated with aging. Worsening social functioning was correlated with high BMI, while worsening role physical and role emotional were not. Hyperglycemia is associated with obesity, while plasma pentosidine levels are inversely correlated with BMI [31]. Indeed, high plasma pentosidine levels may lower QOL through an obesity-independent mechanism. Plasma pentosidine is a type of AGE associated with diabetes [32,33]. AGE accumulation can induce inflammation and aberrant signaling in cells, thereby impairing neurological functions [34,35]. Similarly to hyperglycemia, upregulated plasma pentosidine-induced inflammation and neurological function impairment may adversely affect QOL. Moreover, pentosidine is a cross-linking AGE induced by the oxidation of bone collagen cross-links [36]. Serum pentosidine levels are negatively correlated with muscle mass in menopausal women with type 2 diabetes [37]. Additionally, upregulated levels of serum carboxymethyl-lysine, another AGE product, was negatively correlated with walking ability in elderly women [38]; this effect is, among others, attributed to the increased number of AGE receptors in the muscle tissue with age.
and AGE-mediated inhibition of muscle synthesis [39]. This suggests that pentosidine is associated with both bone quality and physical function [40]. In addition to inhibiting the upregulation of blood glucose levels, strategies that decrease plasma pentosidine levels can reduce the risk of physical limitations.

Plasma pentosidine is also a renal function marker [32,33]. Sarcopenia, characterized by the progressive age-related loss of muscle mass coupled with decreased muscle function, is prevalent among patients with chronic kidney disease (CKD) [41]. The unfavorable outcomes of sarcopenia have attracted attention [42]; sarcopenia-associated loss of skeletal muscle has significant consequences in CKD even prior to initiating dialysis therapy [43]. CKD-associated sarcopenia results from an altered balance between catabolic and anabolic processes that regulate muscle homeostasis [44]. The regulation of homeostasis is a complex process involving hormonal and immunological factors, progenitor cell function, mitochondrial dysfunction, inflammation, metabolic acidosis, malnutrition, physical inactivity, angiotensin II upregulation, and growth factors [44]. These components vary according to the progression of CKD [44]. As sarcopenia and low muscle strength are associated with a poor QOL [45,46], renal function may influence the negative correlation between QOL and plasma pentosidine levels, although the underlying mechanisms remain to be determined.

It was suggested that digital solutions should be developed to fully support the psychophysical well-being of patients with diabetes mellitus [47]. Furthermore, our results suggested that a self-management system and intervention method for glycation prevention can help to improve QOL in the general population.

This study has some limitations. As this was a cross-sectional study, the causal relationship between the factors associated with the decline in QOL could not be determined. The correlation between decreased QOL and plasma pentosidine levels has not been previously assessed. We included individuals who voluntarily participated in the Iwaki Health Promotion Medical Examination Project [15]; thus, the results of this study cannot be generalized due to selection bias. Additional studies are warranted to clarify the relationship between decreased QOL and glycation biomarkers, particularly plasma pentosidine, in the general population using longitudinal data from a large cohort.

5. Conclusions

In the general Japanese population, levels of diabetes-related biomarkers such as blood glucose, HOMA-IR, HbA1c, glycoalbumin, and plasma pentosidine were associated with SF-36 scores in the study cohort. Particularly, the levels of the glycation marker plasma pentosidine were associated with lower SF-36 scores compared to other diabetes-related markers. Our results suggest that the QOL of the general population can be improved by preventing glycation in addition to controlling blood glucose levels.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijerph19159391/s1, Table S1: Correlation between SF-36 scores and age, sex, or BMI.

Author Contributions: M.T. analyzed and interpreted the data, designed the analyses, and contributed to the drafting of the manuscript; M.T., M.N., K.M., T.I. and Y.T. contributed to data acquisition and interpretation. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by JST’s COI program Hirosaki University Base, grant number JPMJCE1302, and FANCL Co., Inc. (Kanagawa, Japan).

Institutional Review Board Statement: This study was approved by the Ethics Review Board of Hirosaki University School of Medicine (approval numbers: 2019-009) and conducted according to the principles of the Declaration of Helsinki.

Informed Consent Statement: Written informed consent has been obtained from the patients to publish this paper.
Data Availability Statement: The data reported in this study cannot be shared publicly because of ethical concerns. Data are available from the Hiroshi University COI Program Institutional Data Access/Ethics Committee (contact via e-mail: coi@hirosaki-u.ac.jp) for researchers who meet the criteria for access to the data. Researchers need to be approved by the research ethics review board of the organization of their affiliations.

Acknowledgments: The authors would like to thank all the participants of the Iwaki Health Promotion Project.

Conflicts of Interest: M.T. and M.N. were employed by FANCL Co., Ltd. (Tokyo, Japan). The remaining authors declare no conflict of interest. No patents, products under development, or products in the market were declared. The funding organizations did not play any role in the study design, data collection and analysis, decision to publish, or manuscript preparation.

References
1. The World Health Organization Quality of Life assessment (WHOQOL): Position paper from the World Health Organization. Soc. Sci. Med. 1995, 41, 1403–1409. [CrossRef]
2. Ware, J.E. Jr. The status of health assessment 1994. Annu. Rev. Public Health 1995, 16, 327–354. [CrossRef] [PubMed]
3. Rubin, R.R.; Peyrot, M. Quality of life and diabetes. Diabetes Metab. Res. Rev. 1999, 15, 205–218. [CrossRef]
4. Haraldstad, K.; Wahl, A.; Andenas, R.; Andersen, I.R.; Beisland, E.; Borge, C.R.; Engbretsen, E.; Eiesmann, M.; Halvorsrud, L.; Hanssen, T.A.; et al. A systematic review of quality of life research in medicine and health sciences. Qual. Life Res. 2019, 28, 2641–2650. [CrossRef]
5. Staquet, M.; Berzon, R.; Osoba, D.; Machin, D. Guidelines for reporting results of quality of life assessments in clinical trials. Qual. Life Res. 1996, 5, 496–502. [CrossRef]
6. Salomon, J.A.; Wang, H.; Freeman, M.K.; Vos, T.; Flaxman, A.D.; Lopez, A.D.; Murray, C.J.L. Healthy life expectancy for 187 countries, 1990–2010: A systematic analysis for the Global Burden Disease Study 2010. Lancet 2012, 380, 2144–2162. [CrossRef]
7. Phyo, A.Z.Z.; Freak-Poli, R.; Craig, H.; Gasevic, D.; Stocks, N.P.; Gonzalez-Chica, D.A.; Ryan, J. Quality of life and mortality in the general population: A systematic review and meta-analysis. BMC Public Health 2020, 20, 1596. [CrossRef]
8. Kassem, L.S.; Aron, D.C. The assessment and management of quality of life of older adults with diabetes mellitus. Expert Rev. Endocrinol. Metab. 2020, 15, 71–81. [CrossRef]
9. Trikkalinou, A.; Papazafiropoulou, A.K.; Melidonis, A. Type 2 diabetes and quality of life. World J. Diabetes 2017, 8, 120–129. [CrossRef]
10. Alshayban, D.; Joseph, R. Health-related quality of life among patients with type 2 diabetes mellitus in Eastern Province, Saudi Arabia: A cross-sectional study. PLoS ONE 2020, 15, e0227573. [CrossRef]
11. Crandall, J.P.; Knowler, W.C.; Kahn, S.E.; Marrero, D.; Florez, J.C.; Bray, G.A.; Haffner, S.M.; Hoskin, M.; Nathan, D.M. Diabetes Prevention Program Research Group. The prevention of type 2 diabetes. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4, 382–393. [CrossRef] [PubMed]
12. Nouwen, A.; Nefs, G.; Caramlau, I.; Connock, M.; Winkley, K.; Lloyd, C.E.; Peyrot, M.; Pouwer, F. European Depression in Diabetes Research Consortium. Prevalence of depression in individuals with impaired glucose metabolism or undiagnosed diabetes: A systematic review and meta-analysis of the European Depression in Diabetes (EDID) Research Consortium. Diabetes Care 2011, 34, 752–762. [CrossRef] [PubMed]
13. Simó-Servat, O.; Planas, A.; Ciudin, A.; Simó, R.; Hernández, C. Assessment of advanced glycation end-products as a biomarker of diabetic outcomes. Endocrinol. Diabetes Nutr. 2018, 65, 540–545. [CrossRef] [PubMed]
14. Nakaji, S.; Ibara, K.; Sawada, K.; Parodi, S.; Umeda, T.; Takahashi, I.; Murashita, K.; Kurauchi, S.; Tokuda, I. Social innovation for life expectancy extension utilizing a platform-centered system used in the Iwaki health promotion project: A protocol paper. SAGE Open Med. 2021, 9, 20503121211002606. [CrossRef] [PubMed]
15. Tsubokawa, M.; Nishimura, M.; Tamada, Y.; Nakaji, S. Factors Associated with Reduced Heart Rate Variability in the General Japanese Population: The Iwaki Cross-Sectional Research Study. Healthcare 2022, 10, 793. [CrossRef] [PubMed]
16. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28, 412–419. [CrossRef]
17. Breneman, C.B.; Tucker, L. Dietary fibre consumption and insulin resistance—The role of body fat and physical activity. Br. J. Nutr. 2013, 110, 375–383. [CrossRef]
18. Fukuhara, S.; Bito, S.; Green, J.; Hsiao, A.; Kurokawa, K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J. Clin. Epidemiol. 1998, 51, 1037–1044. [CrossRef]
19. Fukuhara, S.; Ware, J.E., Jr.; Kosinski, M.; Wada, S.; Gandek, B. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J. Clin. Epidemiol. 1998, 51, 1045–1053. [CrossRef]
20. Mo, F.; Morrison, H.; Choi, B.C.K.; Vardy, L. Evaluation and measurement of health-related quality of life for individuals with diabetes mellitus by Health Utilities Index Mark 3 (HUI3) system. Sci. World J. 2006, 6, 1412–1423. [CrossRef]
21. Hänninen, J.; Takala, J.; Keinänen-Kiukaanniemi, S. Quality of life in NIDDM patients assessed with the SF-20 questionnaire. Diabetes Res. Clin. Pract. 1998, 42, 17–27. [CrossRef]
22. Schlottz, W.; Ambery, P.; Syddall, H.E.; Crozier, S.R.; Sayer, A.A.; Cooper, C.; Phillips, D.I.W.; Hertfordshire Cohort Study Group. Specific associations of insulin resistance with impaired health-related quality of life in the Hertfordshire Cohort Study. Qual. Life Res. 2007, 16, 429–436. [CrossRef] [PubMed]
23. Ribu, L.; Hanestad, B.R.; Moum, T.; Birkeland, K.; Rustoen, T. A comparison of the health-related quality of life in patients with diabetic foot ulcers, with a diabetes group and a nondiabetes group from the general population. Qual. Life Res. 2007, 16, 179–189. [CrossRef] [PubMed]
24. Adriaanse, M.C.; Dekker, J.M.; Spijkerman, A.M.W.; Twisk, J.W.R.; Nijpels, G.; van der Ploeg, H.M.; Heine, R.J.; Snoek, F.J. Diabetes-related symptoms and negative mood in participants of a targeted population-screening program for type 2 diabetes: The Hoorn Screening Study. Qual. Life Res. 2005, 14, 1501–1509. [CrossRef]
25. Egède, L.E. Effect of comorbid chronic diseases on prevalence and odds of depression in adults with diabetes. Psychosom. Med. 2005, 67, 46–51. [CrossRef] [PubMed]
26. Fujinami, A.; Ohta, K.; ObaYashi, H.; Fukui, M.; Hasegawa, G.; Nakamura, N.; Kozai, H.; Imai, S.; Ohta, M. Serum brain-derived neurotrophic factor in patients with type 2 diabetes mellitus: Relationship to glucose metabolism and biomarkers of insulin resistance. Clin. Biochem. 2008, 41, 812–817. [CrossRef]
27. Krabbe, K.S.; Nielsen, A.R.; Krogh-Madsen, R.; Plomgaard, P.; Rasmussen, P.; EriKstrop, C.; Fischer, C.P.; Lindegaard, B.; Petersen, A.M.W.; Taoudor, S.; et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007, 50, 431–438. [CrossRef] [PubMed]
28. Pickup, J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2007, 30, 1847–1853. [CrossRef] [PubMed]
29. Grandy, S.; Chapman, R.H.; Fox, K.M. SHIELD Study Group. Quality of life and depression of people living with type 2 diabetes mellitus and those at low and high risk for type 2 diabetes: Findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD). Int. J. Clin. Pract. 2008, 62, 562–568. [CrossRef] [PubMed]
30. Foroumandi, E.; Alizadeh, M.; Kheirouri, S.; JafariBadi, M.A. Exploring the role of body mass index in relationship of serum nicotinamide and advanced glycation end products in apparently healthy subjects. PLoS ONE 2019, 14, e0213307. [CrossRef] [PubMed]
31. Sugiyama, S.; Miyata, T.; Ueda, Y.; Tanaka, H.; Maeda, K.; Kawashima, S.; de Strihou, C.V.Y.; Kurokawa, K. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9, 1681–1688. [CrossRef] [PubMed]
32. Ramasamy, R.; Vannucci, S.J.; Yan, S.S.D.; Herold, K.; Yan, S.F.; Schmidt, A.M. Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005, 15, 16R–28R. [CrossRef]
33. Verrotti, A.; LoIacono, G.; Mohn, A.; Chiarelli, F. New insights in diabetic autonomic neuropathy in children and adolescents. Eur. J. Endocrinol. 2009, 161, 811–818. [CrossRef] [PubMed]
34. Saito, M.; Marumo, K.; Tanaka, H.; Maeda, K.; Kawashima, S.; de Strihou, C.V.Y.; Kurokawa, K. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9, 1681–1688. [CrossRef] [PubMed]
35. Verrotti, A.; Loiacono, G.; Mohn, A.; Chiarelli, F. New insights in diabetic autonomic neuropathy in children and adolescents. Eur. J. Endocrinol. 2009, 161, 811–818. [CrossRef] [PubMed]
36. Saito, M.; Marumo, K.; Tanaka, H.; Maeda, K.; Kawashima, S.; de Strihou, C.V.Y.; Kurokawa, K. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9, 1681–1688. [CrossRef] [PubMed]
37. Ramasamy, R.; Vannucci, S.J.; Yan, S.S.D.; Herold, K.; Yan, S.F.; Schmidt, A.M. Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005, 15, 16R–28R. [CrossRef]
38. Saito, M.; Marumo, K.; Tanaka, H.; Maeda, K.; Kawashima, S.; de Strihou, C.V.Y.; Kurokawa, K. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9, 1681–1688. [CrossRef] [PubMed]
39. Verrotti, A.; Loiacono, G.; Mohn, A.; Chiarelli, F. New insights in diabetic autonomic neuropathy in children and adolescents. Eur. J. Endocrinol. 2009, 161, 811–818. [CrossRef] [PubMed]
40. Saito, M.; Marumo, K.; Tanaka, H.; Maeda, K.; Kawashima, S.; de Strihou, C.V.Y.; Kurokawa, K. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9, 1681–1688. [CrossRef] [PubMed]
41. Saito, M.; Marumo, K.; Tanaka, H.; Maeda, K.; Kawashima, S.; de Strihou, C.V.Y.; Kurokawa, K. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9, 1681–1688. [CrossRef] [PubMed]
42. Saito, M.; Marumo, K.; Tanaka, H.; Maeda, K.; Kawashima, S.; de Strihou, C.V.Y.; Kurokawa, K. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9, 1681–1688. [CrossRef] [PubMed]
43. Saito, M.; Marumo, K.; Tanaka, H.; Maeda, K.; Kawashima, S.; de Strihou, C.V.Y.; Kurokawa, K. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9, 1681–1688. [CrossRef] [PubMed]
44. Saito, M.; Marumo, K.; Tanaka, H.; Maeda, K.; Kawashima, S.; de Strihou, C.V.Y.; Kurokawa, K. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9, 1681–1688. [CrossRef] [PubMed]
45. Saito, M.; Marumo, K.; Tanaka, H.; Maeda, K.; Kawashima, S.; de Strihou, C.V.Y.; Kurokawa, K. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9, 1681–1688. [CrossRef] [PubMed]
46. Saito, M.; Marumo, K.; Tanaka, H.; Maeda, K.; Kawashima, S.; de Strihou, C.V.Y.; Kurokawa, K. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9, 1681–1688. [CrossRef] [PubMed]
47. Saito, M.; Marumo, K.; Tanaka, H.; Maeda, K.; Kawashima, S.; de Strihou, C.V.Y.; Kurokawa, K. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9, 1681–1688. [CrossRef] [PubMed]
48. Saito, M.; Marumo, K.; Tanaka, H.; Maeda, K.; Kawashima, S.; de Strihou, C.V.Y.; Kurokawa, K. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9, 1681–1688. [CrossRef] [PubMed]
49. Saito, M.; Marumo, K.; Tanaka, H.; Maeda, K.; Kawashima, S.; de Strihou, C.V.Y.; Kurokawa, K. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9, 1681–1688. [CrossRef] [PubMed]
44. Avin, K.G.; Moorthi, R.N. Bone is not alone: The effects of skeletal muscle dysfunction in chronic kidney disease. *Curr. Osteoporos. Rep.* 2015, 13, 173–179. [CrossRef] [PubMed]

45. Tsekoura, M.; Kastrinis, A.; Katsoulaki, M.; Billis, E.; Gliatis, J. Sarcopenia and its impact on quality of life. *Adv. Exp. Med. Biol.* 2017, 987, 213–218. [CrossRef]

46. Beaudart, C.; Biver, E.; Bruyère, O.; Cooper, C.; Al-Daghri, N.; Reginster, J.Y.; Rizzoli, R. Quality of life assessment in musculoskeletal health. *Aging Clin. Exp. Res.* 2018, 30, 413–418. [CrossRef]

47. Bassi, G.; Mancinelli, E.; Dell’Arciprete, G.; Rizzi, S.; Gabrielli, S.; Salcuni, S. Efficacy of eHealth Interventions for Adults with Diabetes: A Systematic Review and Meta-Analysis. *Int. J. Environ. Res. Public Health* 2021, 18, 8982. [CrossRef]